Although immune checkpoint inhibitors (ICIs) targeting axes such as PD-1/PD-L1 have revolutionized therapeutic paradigms, patient response rates remain constrained by the dynamic heterogeneity of the tumor microenvironment (TME) (2). Here, CD274 is linked to neoplasm.